ABCELLERA BIOLOGICS INC
NASDAQ: ABCL (AbCellera Biologics Inc.)
Last update: 9 hours ago2.41
-0.08 (-3.21%)
Previous Close | 2.49 |
Open | 2.52 |
Volume | 3,261,534 |
Avg. Volume (3M) | 4,162,235 |
Market Cap | 719,201,856 |
Price / Sales | 24.81 |
Price / Book | 0.680 |
52 Weeks Range | |
Earnings Date | 8 May 2025 |
Operating Margin (TTM) | -807.03% |
Diluted EPS (TTM) | -0.550 |
Quarterly Revenue Growth (YOY) | -45.00% |
Total Debt/Equity (MRQ) | 6.19% |
Current Ratio (MRQ) | 9.81 |
Operating Cash Flow (TTM) | -108.56 M |
Levered Free Cash Flow (TTM) | -177.77 M |
Return on Assets (TTM) | -12.41% |
Return on Equity (TTM) | -14.75% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | AbCellera Biologics Inc. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 1.0 |
Technical Oscillators | 2.0 |
Average | 1.63 |
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 22.88% |
% Held by Institutions | 42.28% |
Ownership
Name | Date | Shares Held |
---|---|---|
Baker Bros. Advisors Lp | 31 Dec 2024 | 27,525,640 |
Baillie Gifford & Co | 31 Dec 2024 | 12,236,465 |
Voya Investment Management Llc | 31 Dec 2024 | 10,624,185 |
Capital World Investors | 31 Dec 2024 | 7,933,613 |
Orbimed Advisors Llc | 31 Dec 2024 | 4,180,768 |
Arrowmark Colorado Holdings Llc | 31 Dec 2024 | 4,105,095 |
Two Sigma Investments, Lp | 31 Dec 2024 | 3,257,311 |
Two Sigma Advisers, Lp | 31 Dec 2024 | 2,608,400 |
Guardian Capital Advisors Lp | 30 Sep 2024 | 1,786,414 |
52 Weeks Range | ||
Price Target Range | ||
High | 10.00 (Stifel, 314.94%) | Buy |
Median | 7.50 (211.20%) | |
Low | 5.00 (Keybanc, 107.47%) | Buy |
Average | 7.50 (211.20%) | |
Total | 2 Buy | |
Avg. Price @ Call | 2.49 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Keybanc | 16 Apr 2025 | 5.00 (107.47%) | Buy | 2.39 |
Stifel | 28 Feb 2025 | 10.00 (314.94%) | Buy | 2.59 |
No data within this time range.
Date | Type | Details |
---|---|---|
29 Apr 2025 | Announcement | AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 |
08 Apr 2025 | Announcement | AbCellera to Participate at Upcoming Investor Conferences in May and June |
03 Apr 2025 | Announcement | AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 |
25 Mar 2025 | Announcement | AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 |
27 Feb 2025 | Announcement | AbCellera Reports Full Year 2024 Business Results |
11 Feb 2025 | Announcement | AbCellera to Participate at Upcoming Investor Conferences in March |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |